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Surgical completeness of total thyroidectomy using 
harmonic scalpel: comparison with conventional total 
thyroidectomy in papillary thyroid carcinoma patients
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Soo Park
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Korea
Purpose: The aim of this study was to compare the surgical completeness and outcome of total thyroidectomy in two patient 
groups: One treated by harmonic scalpel (HS) and one by conventional total thyroidectomy (CT). Methods: Between March 
2006 and December 2007, 104 patients had total thyroidectomy by HS and 108 patients underwent CT. We analyzed clin-
icopathological characteristics and stimulated serum thyroid-stimulating hormone (TSH), thyroglobulin (Tg), and anti-Tg 
antibodies at the time of ablation for both groups. Results: Compared with the CT group, the HS group had shorter operating 
time and hospital stays and reduced postoperative drainage. At postsurgical ablation, mean serum TSH was 80.47 ± 21.77 
mU/L in the HS group and 69.74 ± 21.17 mU/L in the CT group, with significant between-group differences (P ＜ 0.001). Mean 
serum Tg levels after TSH stimulation were 1.57 ± 3.17 and 3.95 ± 10.14 ng/mL in the HS and CT groups, respectively, with 
significant between-group differences (P = 0.028). Conclusion: Total thyroidectomy with an HS is a relatively safe and effec-
tive technique for use in patients with PTC. The HS provides surgical completeness and has a beneficial effect on successful 
ablation. 
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INTRODUCTION
The incidence of papillary thyroid carcinoma (PTC) is 
increasing worldwide, rising 2.9-fold between 1988 and 
2002 in the United States [1]. It is now the most prevalent 
cancer in Korean women [2]. 
With the rising incidence of PTC, there is a need for new 
safe surgical techniques that require less operating time so 
that more patients can be treated in a timely manner.
Although the extent of thyroidectomy remains con-
troversial, total thyroidectomy (TT) has been one of the 
most frequently performed operations for patients with 
PTC. Complete resection of the thyroid gland results in 
fewer loco-regional recurrences and facilitates detection 
of metastatic disease, both by serum thyroglobulin (Tg) 
evaluation and by postablation 131I whole body scan [3,4]. 
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However, TT has more postoperative complications, such 
as permanent recurrent laryngeal nerve (RLN) palsy and 
hypoparathyroidism, than unilateral lobectomy [5]. Since 
development of the harmonic scalpel (HS) in the early 
1990s, it has been used in thyroid surgery to ensure a dry 
surgical field and to satisfy the surgeon’s need for surgical 
efficiency. The synchronous action of the HS for simulta-
neous cutting and coagulation of blood vessels is benefi-
cial in reducing operating time, compared with conven-
tional suture ligation techniques or other vessel sealing 
devices [6-9]. In addition, the capability of the HS to seal 
vessels and assure coagulation at low temperatures 
(between 50°C and 100°C) results in less thermal damage 
to surrounding structures [10]. Previous studies have con-
firmed a reduction in postoperative complications after 
thyroidectomy with HS [11,12].
The HS was initially used in open thyroid surgery for 
treatment of benign or malignant thyroid disease [7]. 
Subsequently, it was shown to be advantageous in mini-
mally invasive endoscopic thyroidectomy [13,14]. To date, 
a number of HS studies in thyroid surgery have been 
published. The majority of studies have shown HS to be 
safe and efficient in terms of perioperative complications 
and hemostasis and time-saving in comparison with con-
ventional suture ligation techniques or other vessel seal-
ing devices. However, we have assessed the impact of HS 
on surgical completeness in TT followed by 131I ablation of 
the thyroid remnant.
This study had two objectives: first, to evaluate and 
compare the surgical efficiency and safety of HS and con-
ventional TT, and second, to determine if there is any dis-
tinction in surgical completeness between the two 
techniques. Toward that end, we measured the mean level 
of serum thyroid-stimulating hormone (TSH) at 131I abla-
tion and the mean level of stimulated serum Tg. To the best 
of our knowledge, this is the first study that has compared 
the HS technique with the conventional technique with re-




We retrospectively reviewed medical records of 701 
consecutive patients who underwent surgery for treat-
ment of PTC between March 2006 and December 2007 in 
the Department of Surgery, Yonsei University College of 
Medicine, by one experienced surgeon (KHN). Preopera-
tive diagnoses of thyroid nodules were made by ultra-
sonographic-guided fine needle aspiration biopsy and 
neck computed tomography.
In October 2006, we began routine use of HS in thyroid 
surgery. Thus, of the 701 patients treated, 200 had conven-
tional total thyroidectomy (CT group; from March to 
September 2006), and 501 had TT by use of  HS (HS group; 
from October 2006 to December 2007).
We excluded patients who underwent less than TT, 
completion thyroidectomy, lateral neck node dissection, 
endoscopic thyroidectomy, or robotic-assisted endoscopic 
thyroidectomy.
In all, a total of 212 PTC patients were selected who met 
the following four inclusion criteria:
1) The TT was performed in our hospital.
2) 131I ablation was performed after surgery without a 
preliminary diagnostic 131I whole body scan.
3) Serum Tg levels in the absence of serum anti-Tg anti-
bodies (TgAb) were determined at the time of 131I ablation 
when serum TSH should be above 30 mU/L, minimal cri-
teria for optimal ablation based on American Thyroid 
Association (ATA) guidelines [15]. Thyroiditis patients 
with positive levels of TgAb were excluded from the study 
due to possible false reduction in measured serum Tg 
levels.
4) Patients had no preoperative or postoperative distant 
metastases.
According to ATA guidelines [15], TT is recommended 
in the following circumstances: 1) primary thyroid cancer 
＞1 cm; 2) presence of contralateral thyroid nodules or re-
gional or distant metastases; 3) history of radiation ther-
apy to the head and neck; 4) patient has a first-degree rela-
tive with differentiated thyroid cancer; 5) age ＞45 years; 
6) presence of extracapsular invasion or multifocality. 
Of the 212 patients with PTC enrolled in this study, 104 
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were in the HS group and 108 in the CT group. All had pro-
phylactic ipsilateral central compartment node dissection 
(CCND). In order to reduce interoperator confounding 
factors, all operations were performed by the same princi-
pal surgeon. The study was approved by the hospital’s 
Institutional Review Board.
Preparation and 131I ablation treatment
After surgery, all patients began treatment with a 
TSH-suppressing dose of LT4 (2 μg/kg). In the present 
study, radioactive iodine (RI) was given therapeutically 
without a diagnostic 131I whole-body scan in order to avoid 
a “stunning effect” (i.e., decreased uptake by a thyroid 
remnant of 131I after diagnostic administration of 131I) [16]. 
RI was administered 6 to 8 weeks after surgery when each 
patient was in hypothyroidism after LT4 had been with-
drawn for 4 weeks. After 2 weeks on a low-iodine diet, all 
patients were treated with 30 mCi of RI. Patients received 
written instructions and were assisted by a dietician. The 
131I whole body scan was done on the second day after RI 
treatment.  
TSH and Tg assay
Stimulated serum Tg, serum TgAb, and serum TSH 
were measured at ablation. Serum TSH was measured by 
chemiluminescence immunoassay (Centaur; Bayer Health 
Care, Mannheim, Germany). Serum Tg was measured by 
immunoradiometric assay (Dynotest TgS, Brahms, Berlin, 
Germany), and, similarly, for TgAbs (Anti-Tgn RIA, 
Brahms). The Tg assay had a sensitivity of 0.2 ng/mL. 
TgAb status was considered negative when readings were 
＜20 IU/mL. 
Surgical technique
TT is defined as total bilateral extracapsular thyro-
idectomy. Each patient was placed in a supine position and 
the neck was extended while the patient was under gen-
eral anesthesia. A 5 to 6 cm transverse collar skin incision 
was made two fingerbreadths above the sternal notch, and 
the lower layer of the platysma was exposed under direct 
vision. Subplatysmal flap dissection was performed for 
achievement of adequate working space from the sternal 
notch to the hyoid bone level superiorly and both medial 
sides of the anterior border of the sternocleidomastoid 
muscle laterally. The midline of the strap muscle was div-
ided vertically, and the thyroid gland was exposed. In pa-
tients assigned to the HS group, only Harmonic ACE 
Curved Shears (23-mm long; Johnson & Johnson Medical, 
Cincinnati, OH, USA) were used for vascular control of the 
thyroid gland. The named vessels of the superior, middle, 
and inferior thyroidal arteries and veins were controlled 
by using a low power level (70 μm vibration). Other small 
vessels and surrounding soft tissues were controlled by 
using a higher power level (100 μm vibration) for easy 
cutting. For patients in the conventional TT group, electro-
cautery was used for control of the small vessels of the 
gland and conventional hand-tied ligation was used for 
the named vessels and some arterial branches. The upper 
pole of the gland was divided carefully in order to avoid 
injury to the superior laryngeal nerves. The greatest atten-
tion was paid to identification of all of the superior and in-
ferior parathyroid glands and to their preservation with 
the intact vascular pedicle. Parathyroid autotransplan-
tation was performed as needed. Careful dissection was 
performed for identification of the inferior thyroid artery 
and the RLN in the usual anatomic relationship. The 
whole cervical course of the RLN was traced and the gland 
was then dissected from the trachea. When CCND (the 
prelaryngeal, pretracheal, and paratracheal area of the tu-
mor side) was performed, while monitoring the RLN 
track, soft tissue and lymph nodes were removed within 
an area limited cranially by the hyoid bone and superior 
thyroid vessels, caudally by the thyro-thymic ligament 
area, and laterally by the medial border of the carotid 
artery. In the HS group, special care was taken to avoid 
damage to the RLN in the tracheoesophageal groove due 
to the collateral energy of the HS. A Jackson-Pratt closed 
suction drain (100 mL, 3.2 mm in diameter; Barovac 
Sewoon Medical, Seoul, Korea) was placed through a sep-
arate skin incision in all patients. This drain was removed 
when drainage decreased to less than 20 mL/day. Wounds 
were closed with absorbable suture material using a con-
tinuous subcutis suture method.
Outcome assessment
Based on clinical and pathologic records, a retrospective 





(n = 108) P-value
Age (yr) 49.04 ± 10.41 49.33 ± 10.01 0.833
Gender 0.178
   Female 93 (89.4)      102 (94.4)
   Male 11 (10.6) 6 (5.6)
Multifocality 0.213
   Yes 45 (43.2) 38 (35.2)
   No 59 (56.8) 70 (64.8)
TNM stage
   T1 46 (44.2) 52 (48.1) 0.712
   T2  1 (0.01)   1 (0.01)
   T3 57 (54.8) 54 (50.0)
   T4a 0 (0)   1 (0.01)
   N0 80 (76.9) 81 (75.0) 0.743
   N1a 24 (23.1) 27 (25.0)
Stage 0.556
   I 59 (56.7) 64 (59.2)
   III 45 (43.3) 43 (39.8)
   IVA 0 (0)   1 (0.01)
Tumor size (cm)  0.80 ± 0.47 1.00 ± 0.61 0.001
No. of LN
   Retrieved  4.41 ± 4.07 4.27 ± 3.85 0.754
   Metastatic  0.61 ± 1.68 0.66 ± 1.56 0.830
Thyroid weight (g) 20.83 ± 8.86 22.12 ± 10.83 0.362
Values are presented as mean ± SD or number (%).
PTC, papillary thyroid carcinoma; HS, harmonic scalpel; CT, 
conventional total thyroidectomy; TNM, tumor-node-metastasis; 
LN, lymph nodes.
Table 1. Comparison of clinicopathological features in two groups 
(HS and CT) of patients with PTC
analysis was performed on numerous variables in both pa-
tient groups. These included demographic and patho-
logical findings, operating time (from skin incision to clo-
sure), intraoperative bleeding, total amount of drainage, 
length of hospital stay, incidence of perioperative compli-
cations (hematoma, RLN palsy, hypoparathyroidism, se-
roma, other injuries), and measurement of stimulated se-
rum Tg, serum TgAb, and serum TSH at the time of 131I 
ablation.
Laryngoscopy was performed preoperatively for evalu-
ation of vocal cord mobility in all patients. Gauze pieces 
were weighed before and after use for estimation of the 
amount of intraoperative bleeding (1 g, 1 mL of blood). 
Postoperative calcium, phosphorus, and parathyroid hor-
mone (PTH) levels were monitored in all patients. 
Hypocalcemia was defined as a serum calcium level ＜8.0 
mg/dL, even in a single measurement. Hypocalcemic pa-
tients received supplementation therapy with oral cal-
cium and vitamin D (calcitriol), even if asymptomatic. 
Supplementation therapy was gradually tapered on the 
basis of serum calcium and PTH measurements in the out-
patient clinic. We defined transient hypocalcemia and 
RLN palsy based on recovery from symptoms and nor-
malization of laboratory data within 6 months.
Statistical analysis
All data were expressed as mean ± standard deviation, 
proportions, or absolute numbers. We used SPSS ver. 13.0 
(SPSS Inc., Chicago, IL, USA) for statistical analysis. 
Statistical differences between the two groups were as-
sessed by the Student’s t-test or the Mann-Whitney test for 
continuous variables, depending on distribution. Inter- 
arm comparisons of categorical variables were performed 
using the chi-square test. P ＜ 0.05 was accepted as a sig-
nificant difference.
RESULTS
Clinicopathological findings of both groups are shown 
in Table 1. The groups were well matched for age and sex 
(P-value, not significant). There were no differences in 
clinicopathological findings, except for tumor size. Mean 
tumor size in the CT group was 1.00 ± 0.61 cm compared 
with 0.80 ± 0.47 cm in the HS group. Although statistically 
significant, the difference was clinically negligible consid-
ering that the actual difference of mean tumor size be-
tween the two groups was only about 0.2 cm and there was 
no difference in T stage.
Mean number of retrieved and pathologically proven 
metastatic central lymph nodes in the HS group were 4.41 
± 4.07 and 0.61 ± 1.68 compared with 4.27 ± 3.85 and 0.66 ± 
1.56 in the CT group. The differences were not statistically 
significant. 
Postoperative outcomes and complications in the 
groups are summarized Table 2. Operating time in the two 
groups was statistically significant (P ＜ 0.001): 87.73 ± 
22.52 minutes in the HS group, 36.23 minutes less than for 
the CT group (123.96 ± 32.17 minutes). The length of hospi-
tal stay in the HS group was significantly shorter than in 





 (n = 108) P-value
Operating time (min) 87.73 ± 22.52 123.96 ± 32.17 ＜0.001
Intraoperative
 bleeding (g)
18.07 ± 12.41   21.05 ± 11.62 0.796
Amount of drainage 
 (mL)
81.12 ± 40.93   94.18 ± 30.68 0.015
Hospital stay (day) 3.51 ± 0.96   4.53 ± 0.91 ＜0.001
Complications
  Transient hypocalcemia 32 (30.7)   36 (33.3) 0.664
  Seroma 8 (7.6)   3 (2.7) 0.107
  Hematoma 1 (0.9) 0 (0) 0.307
Values are presented as mean ± SD or number (%).
Table 2. Comparison of postoperative outcomes and compli-
cations in patients treated by harmonic scalpel (HS) or 
conventional total thyroidectomy (CT)
Normal range HS group (n = 104) CT group (n = 108) P-value
Serum TSH (mU/L)      0.35–4.94   80.47 ± 21.77   69.74 ± 21.17 0.001
Serum Tg (ng/mL) 0–39.2  1.57 ± 3.17    3.95 ± 10.14 0.028
Serum TgAbs (IU/mL) 0–13.7 10.39 ± 6.38 10.40 ± 7.23 0.988
Values are presented as mean ± SD.
TSH, thyroid-stimulating hormone; Tg, thyroglobulin; TgAbs, anti-thyroglobulin antibodies. 
Table 3. Comparison of serum levels of TSH, Tg, and TgAb levels at 131I ablation in patients treated by harmonic scalpel (HS) or conventional
total thyroidectomy (CT)
the CT group (P = 0.001), and the HS group had sig-
nificantly less postoperative drainage (P = 0.001). There 
was no between-group difference in amount of intra-
operative bleeding, transient hypocalcemia, seroma, and 
hematoma. No patient had permanent RLN palsy or 
hypoparathyroidism. All seromas resolved with repeated 
needle aspiration and compression dressings. No major 
hematoma formation occurred, although 1 patient in the 
HS group had a small hematoma, which originated from a 
tiny bleeder in the anterior surface of the strap muscle. The 
hematoma was evacuated at bedside without difficulty.
Serum levels of serum TSH, Tg, and TgAbs at the time of 
131I ablation in the two groups are summarized in Table 3. 
At the time of 131I ablation, mean serum TSH was 80.47 ± 
21.77 mU/L in the HS group and 69.74 ± 21.17 mU/L in the 
CT group, with significant between-group differences (P = 
0.001). Mean serum Tg levels after TSH stimulation were 
1.57 ± 3.17 ng/mL for the HS group and 3.95 ± 10.14 ng/mL 
for the CT group, with significant between-group differ-
ences (P = 0.028). There was no significant difference in se-
rum TgAbs levels between the groups.
DISCUSSION
 Surgeons who treat PTC have always been concerned 
with surgical and oncologic safety. Surgical safety can be 
defined as the best way to reduce perioperative morbidity 
in surgical patients. Oncologic safety can be defined as the 
best way to improve treatment outcome in cancer patients. 
Until now, most reports of use of the HS in thyroid surgery 
have emphasized its utility in terms of time saving and 
perioperative morbidity without demonstrating its onco-
logic safety in relation to surgical completeness. Our study 
included only PTC patients who underwent TT so that we 
could evaluate how effective the HS was in completely re-
moving the diseased thyroid gland.
Our results show the HS was a faster surgical technique 
than CT, saving 36 minutes on average, consistent with 
most studies [6-9,11]. The shorter operating time implies 
the possibility for treatment of more patients in the same 
operative sessions. Ultimately, HS could enable significant 
reduction of patients awaiting surgery in Yonsei Univer-
sity Health System.
Unlike other studies, we did not find statistically less in-
traoperative bleeding in the HS group [11,17,18]. Possibly 
the CT group had too little intraoperative bleeding for de-
tection of a meaningful difference between the groups. 
Our effort to consistently maintain a dry operative field 
through meticulous hemostasis in the CT group could also 
have made the operation easier and resulted in our favor-
able data. 
In this study, the amount of postoperative drainage was 
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less in the HS group than in the CT group, similar to prior 
reports [7,12]. The explanation is that the HS achieves effi-
cient hemostasis and minimal tissue manipulation during 
surgery. The reduction in postoperative drainage after HS 
surgery resulted in 1-day shorter hospital stays for the HS 
group and related cost savings. All patients in the study 
were admitted to the hospital the day before surgery and 
were not discharged until drains were removed.
Despite our positive findings for the use of HS in thy-
roid surgery, the technique has drawbacks. Mallur et al. 
[19] reported that with prolonged activation the HS gen-
erates considerable residual heat that can lead to unin-
tended burning of adjacent tissue and skin. In addition, to 
avoid permanent complications, a safety margin of 3 to 5 
mm is required between the active curved blade and the 
RLN and parathyroid glands [20]. It is recommended that 
the inactive blade be the nearest tip to the nerve during 
cutting and coagulation. In our study, we found no stat-
istical difference in complication rates between the two 
groups. Of particular importance, there were no cases 
with permanent RLN palsy or permanent hypopara-
thyroidism. We attribute this result to our use of HS in thy-
roid surgery only after initial training and overcoming the 
learning curve of a surgeon’s adaption.
Although the extent of thyroidectomy in PTC patients is 
still under debate, Mazzaferri [4] reported that TT was the 
best operation in terms of oncologic safety. Most PTC pa-
tients have TT followed by 131I ablation of the thyroid rem-
nant, resulting in fewer recurrences, improved survival, 
and easier follow-up. Nevertheless, the current opinion is 
that, despite surgeons’ best efforts, TT is rarely achie-
vable. Microscopic or macroscopic thyroid remnants al-
most always remain and 131I treatment is usually necessary 
for ablation of the remnants [21]. 
In the present study, we found that at 131I ablation, pa-
tients in the HS group had higher serum TSH levels and 
lower serum Tg levels than patients in the CT group. 
Theoretically, TSH stimulation of thyroid cells is required 
for optimal imaging with 131I, because elevated TSH stim-
ulates radioiodine uptake in residual thyroid tissue and 
thyroid carcinoma. Therefore, the HS appears to max-
imize the effect of 131I ablation by effectively raising TSH 
levels more than conventional TT. Serum Tg level reflects 
the size of the thyroid remnant. One gram of thyroid tissue 
releases approximately 1 ng/mL of Tg when TSH is ＜0.1 
mU/L and there is a ＞3-fold increase in serum Tg values 
following TSH stimulation [22]. On the basis of this theory, 
mean off Tg levels in the HS and CT groups are 1.57 ng/mL 
and 3.95 ng/mL, respectively, which can be calculated to 
represent approximately 0.52 g of thyroid remnant in the 
HS group and 1.32 g of thyroid remnant in the CT group, 
respectively. Either is within an acceptable range because 
131I ablation treatment with 30 mCi (1100 MBq), the proto-
col used in our hospital, usually destroys the thyroid rem-
nant, providing that it is ＜2 to 3 g [4]. Therefore, the HS 
provided PTC patients with surgical completeness in that 
the optimal treatment goal is to eliminate all malignant 
thyroid tissue. 
We questioned why patients in the HS group showed 
higher serum TSH levels and lower serum Tg levels at 131I 
ablation than those in the CT group. We speculate that a 
considerable amount of residual heat (between 50°C and 
100°C) generated by the HS may be transmitted to the mi-
croscopic thyroid remnant, which may have an additional 
intraoperative ablative effect on remnant thyroid tissue by 
denaturing proteins. Eventually, the intraoperative abla-
tion effect by the HS minimizes the amount of thyroid 
remnant and enhances the efficacy of 131I ablation treat-
ment by increasing TSH levels and decreasing Tg levels. 
The present study had several limitations. The sample 
size was relatively small, and our study included only the 
short-term follow-up outcome because our goal was pri-
marily to evaluate the surgical completeness of the HS 
technique. The short-term follow-up data for evaluating 
the effect by HS make assertions about surgical complete-
ness and oncologic safety unclear. Therefore, large-scale 
randomized trials and long-term follow-up data are re-
quired to confirm our findings before definitive con-
clusions can be made.
In conclusion, TT using the HS is a relatively safe and ef-
ficient technique for use in PTC patients. In addition, the 
HS provides surgical completeness and a beneficial effect 
on successful ablation.
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